Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Harrow Health ( (HROW) ) is now available.
On August 21, 2025, Harrow, Inc. announced the appointment of Andrew R. Boll as President, who will continue his roles as Chief Financial Officer and Secretary. Randall E. Pollard was appointed as Chief Accounting Officer, effective September 1, 2025, bringing over 20 years of experience in financial reporting and corporate accounting leadership. The Board also approved amended bylaws, designating the CEO as the principal executive officer and updating officer roles to align with current governance practices.
The most recent analyst rating on (HROW) stock is a Hold with a $39.00 price target. To see the full list of analyst forecasts on Harrow Health stock, see the HROW Stock Forecast page.
Spark’s Take on HROW Stock
According to Spark, TipRanks’ AI Analyst, HROW is a Neutral.
Harrow Health’s overall stock score is driven by strong technical indicators and positive earnings call highlights, including strategic alliances and revenue growth. However, significant financial performance challenges, particularly in profitability and cash flow, weigh heavily on the score. The negative P/E ratio further impacts the valuation, limiting the stock’s attractiveness.
To see Spark’s full report on HROW stock, click here.
More about Harrow Health
Average Trading Volume: 510,886
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.45B
See more data about HROW stock on TipRanks’ Stock Analysis page.